((1R,3s,5S)-3-(3-(6-(1H-imidazol-2-yl)pyridin-3-yl)-8H-pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidin-5-yl)-8-azabicyclo[3.2.1]octan-8-yl)(4H-1,2,4-triazol-3-yl)methanone | 1421271-42-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: ((1R,3s,5S)-3-(3-(6-(1H-imidazol-2-yl)pyridin-3-yl)-8H-pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidin-5-yl)-8-azabicyclo[3.2.1]octan-8-yl)(4H-1,2,4-triazol-3-yl)methanone
• CAS: 1421271-42-2
• 化学式: C₂₆H₂₃N₁₁O
• 分子量: 505.542
• InChiKey: LOQIPIKMODPFHY-OSYLJGHBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.33
• 重原子数：
  38.0
• 可旋转键数：
  4.0
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  149.43
• 氢给体数：
  3.0
• 氢受体数：
  8.0

文献信息

• [EN] FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS<br/>[FR] COMPOSÉS TRICYCLIQUES FUSIONNÉS COMME INHIBITEURS DE MTOR
  申请人：MERCK SHARP & DOHME

  公开号：WO2013016164A1

  公开（公告）日：2013-01-31

  The present invention relates to certain pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidine and dipyrazolopyrimidine compounds of Formula (I) as inhibitors of mammalian Target Of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP. The compounds may be used in the treatment of cancer and other disorders where mTOR is deregulated. The present invention further provides pharmaceutical compositions comprising the pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidine or dipyrazolopyrimidine compounds.

  本发明涉及某些嘧啶并[1,5-a]吡咯并[3,2-e]嘧啶和二嘧啶嘧啶化合物，其化学式为（I），作为哺乳动物雷帕霉素靶蛋白（mTOR）激酶的抑制剂，mTOR也被称为FRAP、RAFT、RAPT或SEP。这些化合物可用于治疗癌症和其他mTOR异常的疾病。本发明还提供包含嘧啶并[1,5-a]吡咯并[3,2-e]嘧啶或二嘧啶嘧啶化合物的药物组合物。
• FUSED TRICYCLIC COMPOUNDS AS mTOR INHIBITORS
  申请人：Meng Zhaoyang

  公开号：US20140171456A1

  公开（公告）日：2014-06-19

  The present invention relates to certain pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidine and dipyrazolopyrimidine compounds of Formula (I) as inhibitors of mammalian Target Of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP. The compounds may be used in the treatment of cancer and other disorders where mTOR is deregulated. The present invention further provides pharmaceutical compositions comprising the pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidine or dipyrazolopyrimidine compounds.

  本发明涉及某些式（I）的吡唑并[1,5-a]吡咯并[3,2-e]嘧啶和二吡唑嘧啶化合物，作为哺乳动物雷帕霉素靶点（mTOR）激酶的抑制剂，该激酶也被称为FRAP、RAFT、RAPT或SEP。这些化合物可用于治疗癌症和其他mTOR失调的疾病。本发明还提供包含吡唑并[1,5-a]吡咯并[3,2-e]嘧啶或二吡唑嘧啶化合物的制药组合物。
• US8901142B2
  申请人：——

  公开号：US8901142B2

  公开（公告）日：2014-12-02